Blueberry Therapeutics Ltd.

Vaccinex Inc. and Aridis Pharmaceuticals Inc. were the first and second drug developers to launch initial public offerings in the US during the first half of August. And since the warm month is lag

KaNDy Therapeutics has been launched by GlaxoSmithKline PLC spin-off NeRRe Therapeutics Ltd. to maximize a potential breakthrough medicine that could provide a more effective alternative to ho

The U.K.’s protein-scaffold company Avacta Group PLC expects to explore the use of its Affimer proteins as therapeutic agents targeting immune checkpoints such as PDL1, following the raising of

BioHub At Alderley Park: A Bioincubator With A Difference Once an R&D site for AstraZeneca, The BioHub at Alderley Park is now home to a number of emerging biotechs. Absynth Biologics Ltd. aims t